Plant Name: Nuphar lutea
Taxonomic Information:
Plant ID: NPO21679
Plant Latin Name: Nuphar lutea
Taxonomy Genus: Nuphar
Taxonomy Family: Nymphaeaceae
Plant External Links:
NCBI TaxonomyDB:
77113
Plant-of-the-World-Online:
30385379-2
Used in Medicines:
Country/Region:
LebanonTraditional Medicine System:
Medicinal Functions:
Anaphrodisiac; Anodyne; Antiscrophulatic; Antispasmodic; Astringent; Cardiotonic; Demulcent; Hypotensive; Sedative; Vasoconstrictor
Geographical Distribution:
Turkey; Italy; Bangladesh; France; Ireland; Norway; Belarus; Algeria; Germany; Belgium; Spain; Ukraine; Netherlands; Denmark; Poland; Finland; Sweden; Switzerland; Russia; Bulgaria; Romania; Albania; Portugal; Lebanon; Austria; Greece; Hungary
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CNR1; CNR2; | |
| TSHR; | |
| TDP1; ALPL; BLM; TERT; PGD; POLB; | |
| BCL2; | |
| TRPV1; | |
| CA2; CA4; CA12; CA9; CA7; | |
| NR1H4; | |
| NFKB1; | |
| DNMT1; | |
| ABCB1; | |
| SLCO1B1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.710E-12 | 5.900E-08 | CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.353E-10 | 1.825E-06 | CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.605E-10 | 3.690E-06 | CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.322E-07 | 1.800E-04 | ABCB1, CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 5.102E-07 | 5.067E-04 | ALPL, BCL2, BLM, CA2, CA9, CNR1, NFKB1, TRPV1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.188E-06 | 1.035E-03 | BLM, CA12, CA2, CA4, CA7, CA9, DNMT1, NR1H4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.409E-06 | 1.136E-03 | CA2, CA4, CA9, SLCO1B1, TSHR |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 2.945E-06 | 2.069E-03 | BLM, DNMT1, NFKB1, NR1H4, TRPV1, TSHR |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.375E-06 | 2.100E-03 | CA2, CA7 |
| BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 3.375E-06 | 2.100E-03 | BCL2, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 3.375E-06 | 2.100E-03 | CNR1, CNR2 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 4.031E-06 | 2.372E-03 | ALPL, BCL2, CA2, CA9, NFKB1, TRPV1, TSHR |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 6.746E-06 | 3.583E-03 | CNR1, CNR2 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 9.862E-06 | 4.880E-03 | ALPL, CNR1, CNR2, NFKB1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0035094; response to nicotine | 1.150E-05 | 5.563E-03 | BCL2, CNR1, NFKB1 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 1.466E-05 | 6.515E-03 | BCL2, BLM, CA2, CA9, NFKB1, POLB, TDP1, TERT, TRPV1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.687E-12 | 3.843E-10 | CA12, CA2, CA4, CA7, CA9 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 8.336E-07 | 3.418E-05 | SLCO1B1, ABCB1, CA2, NR1H4 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.790E-04 | 4.299E-03 | CNR2, CNR1, TRPV1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.336E-04 | 4.299E-03 | DNMT1, ABCB1, BCL2, NFKB1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 2.622E-04 | 4.299E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; CNR1; ABCB1; |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | CNR1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2; TRPV1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CNR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | CNR1; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | CNR1; TRPV1; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; BCL2; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | CNR1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; BCL2; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; CNR1; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; DNMT1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; BCL2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CNR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | CNR1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DNMT1; ABCB1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; CA9; |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; DNMT1; ABCB1; CA9; BCL2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CNR1; CA2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; |
| C00-D49: Neoplasms | Breast cancer | C50 | TERT; CA9; BCL2; |
| NA: NA | Esophagus sensitivity | NA | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2; CNR1; TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | DNMT1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | CNR1; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2; CNR1; TRPV1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
